News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Biovest International, Inc. Study Backs Non-Hodgkin’s Lymphoma Anti-Cancer Vaccine
June 1, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tampa Bay Business Journal -- Biovest International Inc. said a Phase III clinical study has shown that BiovaxID significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Lung cancer
Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’
April 23, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
April 23, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer
April 22, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
April 22, 2025
·
2 min read
·
Tristan Manalac
